Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting fees and expenses.
The offering, expected to close on August 15, 2025, is being facilitated by Maxim Group LLC as the sole placement agent.
Securities Purchase Agreement
3,225,000 shares of common stock purchased at $1.20 per share.
Gross Proceeds
Approximately $3.9 million expected before deducting fees.
Closing Date
Expected to close on August 15, 2025, subject to customary conditions.
- The offering will provide an infusion of funds for Scienture Holdings, Inc., enabling it to further its pharmaceutical product development and distribution initiatives.
- Maxim Group LLC's role as the sole placement agent highlights the confidence in the offering and the company's strategic direction.
The securities purchase agreement marks a significant milestone for Scienture Holdings, Inc., showcasing investor interest and confidence in the company's growth prospects.